Topical tacalcitol and 308-nm monochromatic excimer light: a synergistic combination for the treatment of vitiligo

$48.00 plus tax (Refund Policy)

Download / Buy Article:

Abstract:

Background/purpose:

To study and compare the efficacy of combined 308-nm monochromatic excimer light (MEL) therapy with tacalcitol vs. that of MEL 308-nm therapy alone in treatment of vitiligo. Methods:

Thirty-eight patients with vitiligo were enrolled in a single-blind, within patient controlled clinical trial. Symmetrical or nearby lesions were randomly applied with either topical tacalcitol cream or vehicle. Each lesion was treated weekly with the 308-nm MEL, for a total of 12 sessions. Patients were examined at monthly intervals. The mean number of sessions and the cumulative dosage for initial repigmentation were calculated. Result:

Thirty-five patients were evaluated. Treatment with tacalcitol and MEL resulted in higher percentages for excellent repigmentation (25.7%) compared with vehicle and MEL (5.7%) (P<0.05). Percentages for total response were 71.4% and 60%, respectively (P>0.05). The mean±SEM cumulative dose and number of excimer light exposures for initial repigmentation were, respectively, 3.93±0.59 J/cm2 and 4.52±0.49 at the tacalcitol side, and, respectively, 4.99±0.68 J/cm2 and 5.3±0.52 at the vehicle side (P<0.05). Conclusion:

Our results have shown that concurrent topical tacalcitol potentiates the efficacy of the 308-nm MEL in the treatment of vitiligo, and that this combination achieves earlier pigmentation with a lower total dosage.

Keywords: 308-nm MEL; tacalcitol; vitiligo

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1600-0781.2006.00250.x

Affiliations: Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China

Publication date: December 1, 2006

Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more